Early Cardiac Changes in Children with Anderson–Fabry Disease

  • Stepan Havranek
  • Ales Linhart
  • Zuzana Urbanova
  • Uma RamaswamiEmail author
Research Report
Part of the JIMD Reports book series (JIMD, volume 11)


Objective: Limited evidence is available about the early cardiac manifestation of Fabry disease (FD) in children. We aimed to evaluate cardiac involvement in children with FD by analysing serial structural and electrocardiographic changes.

Methods: The data were acquired from 22 children with FD [11 males; median age 9.8 (ranging 2.5–16) years]. Seven patients (5 males) were on enzyme replacement therapy (ERT) with Agalasidase alpha. Echocardiography, ECG and 24-h ECG monitoring recordings were acquired during routine annual clinical controls. ECG data were compared to a group of age-and gender-matched controls.

Results: At baseline, ECG and ECHO parameters of left ventricular mass were similar in both males and females. Three boys (all were on ERT) developed left ventricular hypertrophy (LVH) during two-year follow-up. The progression to LVH was accompanied by the appearance of frequent ventricular premature beats in two cases and supraventricular premature beats (SPBs) with T wave inversion in one case. T wave inversion and SPBs were detected in two younger relatives of a patient with LVH, in the absence of detectable LVH. Seven out of 22 patients had T wave abnormalities. Five of them were males (p = 0.03) all carrying the N215S mutation (p = 0.03). At baseline, median PR intervals were prolonged in FD subjects compared to controls [143 (122–177) vs. 122 (82–165) ms; p < 0.0001].

Conclusions: Cardiac complications of FD become apparent in childhood as subtle changes with slow but detectable progression over time, with males more frequently affected than females. Progression of LVH was apparent in three children despite ERT.


Left Ventricular Hypertrophy Left Ventricular Mass Enzyme Replacement Therapy Fabry Disease Wave Inversion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



AV block




Enzyme replacement therapy


Fabry disease

Holter ECG

24-h ECG monitoring


Heart rate


Left ventricle


Left ventricular hypertrophy




Supraventricular premature beats


Uma Ramaswami


Ventricular premature beats





We thank the metabolic nurses and the cardiology technicians at Addenbrooke’s Hospital for their help with collating data and performing cardiac ECHO and Holter monitoring.


  1. Aryana A, Fifer MA, Ruskin JN, Mela T (2008) Short PR interval in the absence of preexcitation: a characteristic finding in a patient with Fabry disease. Pacing Clin Electrophysiol 31:782–783PubMedCrossRefGoogle Scholar
  2. Barbey F, Qanadli SD, Juli C et al (2010) Aortic remodelling in Fabry disease. Eur Heart J 31:347–353PubMedCrossRefGoogle Scholar
  3. Brady RO, Schiffmann R (2000) Clinical features of and recent advances in therapy for Fabry disease. JAMA 248:2771–2775CrossRefGoogle Scholar
  4. Cybulla M, Walter K, Neumann HP et al (2007) Fabry disease: demographic data since introduction of enzyme replacement therapy. Dtsch Med Wochenschr 132:1505–1509PubMedCrossRefGoogle Scholar
  5. Desnick RJ, Brady R, Barranger J et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338–346PubMedCrossRefGoogle Scholar
  6. Devereux RB, Alonso DR, Lutas EM et al (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450–458PubMedCrossRefGoogle Scholar
  7. Dickinson DF (2005) The normal ECG in childhood and adolescence. Heart 91:1626–1630PubMedCrossRefGoogle Scholar
  8. Dickinson DF, Scott O (1984) Ambulatory electrocardiographic monitoring in 100 healthy teenage boys. Br Heart J 51:179–183PubMedCrossRefGoogle Scholar
  9. Douglas PS, Garcia MJ, Haines DE et al (2011) ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. J Am Soc Echocardiogr 24:229–267PubMedCrossRefGoogle Scholar
  10. Elliott PM, Kindler H, Shah JS et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360PubMedCrossRefGoogle Scholar
  11. Elliott P, Baker R, Pasquale F et al (2011) Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey. Heart 97:1957–1960PubMedCrossRefGoogle Scholar
  12. Eng CM, Niehaus DJ, Desnick RJ (1993a) Molecular analysis of classical and variant phenotypes. Pediatr Res 33:128AGoogle Scholar
  13. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ (1993b) Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53:1186–1197PubMedGoogle Scholar
  14. Frustaci A, Chimenti C (2007) Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation 116:350–351CrossRefGoogle Scholar
  15. Jastrzebski M, Bacior B, Dimitrow PP, Kawecka-Jaszcz K (2006) Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace 8:1045–1047PubMedCrossRefGoogle Scholar
  16. Kampmann C, Baehner F, Whybra C et al (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40:1668–1674PubMedCrossRefGoogle Scholar
  17. Kampmann C, Linhart A, Baehner F et al (2008a) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367–373PubMedCrossRefGoogle Scholar
  18. Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008b) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463–469PubMedCrossRefGoogle Scholar
  19. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 22:709–714PubMedCrossRefGoogle Scholar
  20. Kleinert J, Dehout F, Schwarting A et al (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19:782–787PubMedCrossRefGoogle Scholar
  21. Linhart A, Palecek T, Bultas J et al (2000) New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J 139:1101–1108PubMedCrossRefGoogle Scholar
  22. Linhart A, Magage S, Palecek T, Bultas J (2002) Cardiac involvment in Fabry disease. Acta Paediatr Suppl 91:15–20PubMedCrossRefGoogle Scholar
  23. Mehta J, Tuna N, Moller JH, Desnick RJ (1977) Electrocardiographic and vectorcardiographic abnormalities in Fabry’s disease. Am Heart J 93:699–705PubMedCrossRefGoogle Scholar
  24. Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996PubMedCrossRefGoogle Scholar
  25. Monserrat L, Gimeno-Blanes JR, Marin F et al (2007) Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 50:2399–2403PubMedCrossRefGoogle Scholar
  26. Nagueh SF (2003) Fabry disease. Heart 89:819–820PubMedCrossRefGoogle Scholar
  27. Namdar M, Kampmann C, Steffel J et al (2010) PQ interval in patients with Fabry disease. Am J Cardiol 105:753–756PubMedCrossRefGoogle Scholar
  28. Namdar M, Steffel J, Vidovic M et al (2011) Electrocardiographic changes in early recognition of Fabry disease. Heart 97:485–490PubMedCrossRefGoogle Scholar
  29. O`Connor M, McDaniel N, Brady W (2008) The pediatric electrocardiogram Part I. Am J Emerg Med 26:221–228CrossRefGoogle Scholar
  30. O'Mahony C, Coats C, Cardona M et al (2011) Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace 13:1781–1788PubMedCrossRefGoogle Scholar
  31. Patel MR, Cecchi F, Cizmarik M et al (2011) Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol 57:1093–1099PubMedCrossRefGoogle Scholar
  32. Pochis WT, Litzow JT, King BG, Kenny D (1994) Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol 74:203–204PubMedCrossRefGoogle Scholar
  33. Ramaswami U, Whybra C, Parini R et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95:86–92PubMedCrossRefGoogle Scholar
  34. Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M (2012) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 81:485–490PubMedCrossRefGoogle Scholar
  35. Ries M, Ramaswami U, Parini R et al (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162:767–772PubMedCrossRefGoogle Scholar
  36. Ries M, Clarke JTR, Whybra C et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932PubMedCrossRefGoogle Scholar
  37. Rijnbeek PR, Witsenburg M, Schrama E, Hess J, Kors JA (2001) New normal limits for the paediatric electrocardiogram. Eur Heart J 22:702–711PubMedCrossRefGoogle Scholar
  38. Rijnbeek PR, Herpen G, Kapusta L, Harkel DJ, Witsenburg M, Kors JA (2008b) Electrocardiographic criteria for left ventricular hypertrophy in children. Pediatr Cardiol 29:923–928PubMedCrossRefGoogle Scholar
  39. Sachdev B, Takenaka T, Teraguchi H et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105:1407–1411PubMedCrossRefGoogle Scholar
  40. Scott O, Williams GJ, Fiddler GI (1980) Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 44:304–308PubMedCrossRefGoogle Scholar
  41. Shah JS, Hughes DA, Sachdev B et al (2005) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842–846PubMedCrossRefGoogle Scholar
  42. Southall DP, Johnston F, Shinebourne EA, Johnston PGB (1981) 24-hour electrocardiographic study of heart rate and rhythm patterns in population of healthy children. Br Heart J 45: 281–291PubMedCrossRefGoogle Scholar
  43. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW (2009) Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 119:2561–2567PubMedCrossRefGoogle Scholar
  44. Tøndel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51:767–776PubMedCrossRefGoogle Scholar
  45. Weidemann F, Breunig F, Beer M et al (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227PubMedCrossRefGoogle Scholar
  46. Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Stepan Havranek
    • 1
  • Ales Linhart
    • 1
  • Zuzana Urbanova
    • 2
  • Uma Ramaswami
    • 3
    Email author
  1. 1.Department of Medicine – Department of Cardiovascular Medicine, First Faculty of MedicineCharles University in Prague and General University Hospital in PraguePragueCzech Republic
  2. 2.Department of Paediatrics and Adolescent Medicine, First Faculty of MedicineCharles University in Prague and General University Hospital in PraguePragueCzech Republic
  3. 3.Willink Biochemical Genetics UnitCentral Manchester University Hospitals, NHS Foundation TrustManchesterUK

Personalised recommendations